文献速递肿瘤 PET/CT

[18F]FAPI-42 PET显像在癌症患者中的应用:最佳采集时间、体内分布及与[68Ga]Ga-FAPI-04的比较

[18F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [68Ga]Ga-FAPI-04.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-12-11

22例多种癌症患者接受[18F]FAPI-42全身PET/CT,其中4例完成早期动态20分钟、静态1小时和静态2小时扫描,12例同时接受[18F]FAPI-42与[68Ga]Ga-FAPI-04 PET/CT对比。结果显示[18F]FAPI-42最佳采集时间为注射后1小时,对144个阳性病灶的检出能力与[68Ga]Ga-FAPI-04相同,且在肝脏和骨病灶中SUVmax更高、在肝脏、骨、淋巴结、胸膜和腹膜病灶中TBR更高。

要点

  • [18F]FAPI-42最佳图像采集时间为注射后1小时。
  • [18F]FAPI-42对144个阳性病灶的检出能力与[68Ga]Ga-FAPI-04相同。
  • [18F]FAPI-42在肝脏和骨病灶中SUVmax更高(P < 0.05)。

核心结论

  • 本研究表明[18F]FAPI-42的最佳图像采集时间为注射后1小时,且[18F]FAPI-42对病灶的检出能力与[68Ga]Ga-FAPI-04相当。

研究设计与样本

  • 共纳入22例多种类型癌症患者接受[18F]FAPI-42全身PET/CT,其中4例完成早期动态20分钟、静态1小时和静态2小时扫描,12例同时接受[18F]FAPI-42与[68Ga]Ga-FAPI-04 PET/CT对比。

主要发现

  • [18F]FAPI-42在肿瘤中的摄取迅速,18分钟时平均SUVmax达15.8,并维持在与2小时相似的高水平。
  • [18F]FAPI-42对144个阳性病灶的检出能力与[68Ga]Ga-FAPI-04相同。
  • [18F]FAPI-42在肝脏和骨病灶中SUVmax高于[68Ga]Ga-FAPI-04(P < 0.05)。
  • [18F]FAPI-42在肝脏、骨、淋巴结、胸膜和腹膜病灶中TBR高于[68Ga]Ga-FAPI-04(均P < 0.05)。

关键数值与推荐

  • [18F]FAPI-42最佳图像采集时间确定为注射后1小时。
  • [18F]FAPI-42 18分钟时肿瘤平均SUVmax为15.8。
  • [18F]FAPI-42与[68Ga]Ga-FAPI-04对144个阳性病灶检出能力相同。
  • [18F]FAPI-42肝脏和骨病灶SUVmax高于[68Ga]Ga-FAPI-04(P < 0.05)。
  • [18F]FAPI-42肝脏、骨、淋巴结、胸膜和腹膜病灶TBR高于[68Ga]Ga-FAPI-04(均P < 0.05)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: [18F]FAPI-42 is a new fibroblast activation protein (FAP)-specific tracer used for cancer imaging. Here, we describe the optimal acquisition time and in vivo evaluation of [18F]FAPI-42 and compared intra-individual biodistribution, tumor uptake, and detection ability to [68Ga]Ga-FAPI-04. METHODS: A total of 22 patients with various types of cancer received [18F]FAPI-42 whole-body positron emission tomography/computed tomography (PET/CT). Among them, 4 patients underwent PET/CT scans, including an early dynamic 20-min, static 1-h, and static 2-h scans. The in vivo biodistribution in normal organs and tumor uptake were semiquantitatively evaluated using the standardized uptake value (SUV) and tumor-to-background ratio (TBR). Furthermore, both [18F]FAPI-42 and [68Ga]Ga-FAPI-04 PET/CT were performed in 12 patients to compare biodistribution, tumor uptake, and tumor detection ability. RESULTS: [18F]FAPI-42 uptake in the tumors was rapid and reached a high level with an average SUVmax of 15.8 at 18 min, which stayed at a similarly high level to 2 h. The optimal image acquisition time for [18F]FAPI-42 was determined to be 1 h postinjection. For tumor detection, [18F]FAPI-42 had a high uptake and could be clearly visualized in the lesions. Compared to [68Ga]Ga-FAPI-04, [18F]FAPI-42 had the same detectability for 144 positive lesions. In addition, [18F]FAPI-42 showed a higher SUVmax in liver and bone lesions (P < 0.05) and higher TBRs in liver, bone, lymph node, pleura, and peritoneal lesions (all P < 0.05). CONCLUSION: The present study demonstrates that the optimal image acquisition time of [18F]FAPI-42 is 1 h postinjection and that [18F]FAPI-42 exhibits comparable lesion detectability to [68Ga]Ga-FAPI-04. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2100045757).

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Hu K, Wang L, Wu H, et al. [18F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [68Ga]Ga-FAPI-04. Eur J Nucl Med Mol Imaging. 2021. PMID: 34893920. doi:10.1007/s00259-021-05646-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。